Black Seed Oil / Thymoquinone (ThymoQuin®)

Nigella sativa
Evidence Level
Strong
3 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

Nigella sativa (black seed, black cumin, kalonji) is an annual flowering plant whose seeds have been used medicinally for over 3,300 years — referenced in ancient Egyptian texts and Islamic prophetic medicine as a cure for 'everything except death.' Its primary bioactive compound, thymoquinone (TQ), demonstrates potent antioxidant, anti-inflammatory, immunomodulatory, anti-diabetic, and antimicrobial properties in an impressive body of clinical research. ThymoQuin® (TriNutra) is a standardized, high-thymoquinone cold-pressed black seed oil with verified TQ content and human safety data.

Studied Dose 450–2,000 mg/day black seed oil; ThymoQuin® clinical doses: 450–900 mg/day; most RCTs use 1–2 g/day whole seed or oil; standardize to TQ content for dosing
Active Compound Thymoquinone (TQ, ≥3%) and thymohydroquinone — ThymoQuin® by TriNutra (cold-pressed Nigella sativa oil, standardized ≥3% thymoquinone; also available as seed powder standardized for TQ)

Immune system modulation and respiratory health

Black seed oil significantly enhances NK cell activity, T-cell proliferation, and macrophage function while simultaneously reducing excessive inflammatory cytokine production — a balanced immunomodulatory profile ideal for both immune deficiency and autoimmune-type conditions. Clinical trials show reduced frequency and severity of respiratory infections, improved asthma control, and reduced allergic rhinitis symptoms.

Blood sugar regulation and insulin sensitivity

Meta-analyses of 23+ RCTs confirm black seed significantly reduces fasting blood glucose (by 1.5–2.0 mmol/L), HbA1c, and insulin resistance in type 2 diabetic and pre-diabetic patients. The mechanisms include thymoquinone-mediated beta-cell protection, GLUT4 upregulation, and alpha-glucosidase inhibition — multiple complementary pathways.

Anti-inflammatory and antioxidant protection

Thymoquinone inhibits NF-κB, COX-1/2, 5-LOX, and reduces TNF-α, IL-6, and CRP across multiple clinical studies. The antioxidant mechanism combines direct free radical scavenging with Nrf2 activation and glutathione upregulation — providing comprehensive oxidative stress reduction with clinical evidence in multiple inflammatory conditions.

Lipid profile improvement

Multiple RCTs demonstrate black seed oil significantly reduces total cholesterol, LDL, and triglycerides while increasing HDL — with meta-analyses confirming consistent effects across populations. The lipid-lowering mechanism involves HMG-CoA reductase inhibition, improved LDL receptor expression, and reduced lipid peroxidation.

Blood pressure reduction

A meta-analysis of 11 RCTs confirms black seed significantly reduces both systolic (-2.85 mmHg) and diastolic (-2.49 mmHg) blood pressure. Thymoquinone produces vasodilation via nitric oxide release and calcium channel blocking activity, providing a dual antihypertensive mechanism.

1

Thymoquinone NF-κB and inflammatory cascade inhibition

Thymoquinone directly inhibits IκB kinase (IKK), preventing NF-κB nuclear translocation and the subsequent transcription of TNF-α, IL-1β, IL-6, COX-2, and iNOS. Simultaneously, TQ inhibits 5-lipoxygenase (5-LOX), reducing leukotriene production for dual pathway anti-inflammatory coverage — explaining efficacy across allergic, autoimmune, and metabolic inflammatory conditions.

2

Nrf2 activation and glutathione upregulation

Thymoquinone activates the Nrf2-Keap1 antioxidant response pathway, inducing expression of glutathione peroxidase, glutathione S-transferase, catalase, and heme oxygenase-1. This endogenous antioxidant amplification effect is sustained for 24–48 hours per dose, providing continuous cellular protection beyond direct free radical scavenging.

3

PPAR-γ activation and insulin sensitization

Thymoquinone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) — the same nuclear receptor targeted by thiazolidinedione diabetes drugs — increasing adiponectin production, improving insulin sensitivity, reducing hepatic glucose production, and promoting favorable fat distribution. This explains the comprehensive metabolic benefits of black seed supplementation.

1
Black Seed and Type 2 Diabetes — Meta-Analysis of 23 RCTs
PubMed

Systematic review and meta-analysis of 23 RCTs examining Nigella sativa supplementation on glycemic control in T2DM patients.

Pooled data from 23 RCTs across diverse T2DM populations.

Black seed significantly reduced fasting blood glucose (WMD: -1.61 mmol/L), 2-hour postprandial glucose (-2.39 mmol/L), and HbA1c (-0.45%). Effects consistent across seed powder and oil forms. No serious adverse events in any trial. Supports black seed as effective adjunct for diabetes management.

2
Black Seed Oil and Asthma Control — RCT
PubMed

Randomized, double-blind, placebo-controlled trial of Nigella sativa oil (15 mg/kg/day) vs. placebo in 80 asthmatic adults for 3 months.

80 adult asthma patients. 3-month intervention.

Black seed oil significantly reduced asthma symptom frequency and severity, reduced wheeze, improved pulmonary function tests (FEV1, FVC), and lowered eosinophil count. 54% of patients showed significant improvement vs. 20% placebo. Well-tolerated.

3
Nigella sativa and Lipid Profile — Meta-Analysis of 17 RCTs
PubMed

Meta-analysis of 17 RCTs examining black seed effects on lipid parameters.

Pooled data from 17 RCTs.

Black seed significantly reduced total cholesterol (-15.4 mg/dL), LDL (-14.1 mg/dL), triglycerides (-20.6 mg/dL), and increased HDL (+1.6 mg/dL). Seed powder showed stronger effects than oil in head-to-head analyses. Dose-dependent relationship confirmed.

Common Potential side effects

Generally well tolerated at standard doses; centuries of safe traditional use
GI discomfort, nausea, or heartburn with high doses — take with food
May cause contact dermatitis with topical application in sensitive individuals
Avoid therapeutic doses during pregnancy — historically used to stimulate uterine contractions at high doses

Important Drug interactions

Antidiabetic medications (insulin, metformin) — significant additive glucose-lowering; monitor blood sugar carefully; dose adjustment may be needed
Anticoagulants (warfarin) — thymoquinone inhibits platelet aggregation and may inhibit CYP2C9; monitor INR closely
Antihypertensive medications — additive blood pressure-lowering; monitor blood pressure
Cyclosporine — TQ inhibits CYP3A4 and P-glycoprotein; may significantly increase cyclosporine levels; avoid combining in transplant patients